Operating cash flow turned positive at $9.7M in Q2 2026, but this was driven by a $15.2M working capital benefit, and cumulative FCF over the last four quarters is -$9.9M, highlighting volatility.
Starling Oncology, Inc. (STLN) cash flow statement — 7-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 |
|---|
| Cash from Operations | 33.07M | -24.59M | -26.54M | -36.31M | -61.76M | -32.68M | 508K | 3.62M |
| Operating CF Margin % | - | -4.89% | -6.75% | -11.2% | -24.46% | -16.1% | 0.27% | 2.33% |
| Operating CF Growth % | 259.27% | - | 26.92% | 41.2% | -88.97% | -6533.07% | -85.95% | - |
| Net Income | -35.54M | -60.61M | -53.01M | -83.07M | 152K | -10.93M | -14.32M | -4.02M |
| Depreciation & Amortization | 9.96M | 6.94M | 6.29M | 5.87M | 4.41M | 3.34M | 3.18M | 2.94M |
| Stock-Based Compensation | 8.18M | 4.55M | 11.15M | 17.81M | 27.68M | 24.54M | 151K | 94.01K |
| Deferred Taxes | 0 | -32K | 0 | -76K | -263K | -1.24M | -1.34M | 824.76K |
| Other Non-Cash Items | 39.54M | 23.23M | 2.12M | 20.79M | -73.2M | -33.9M | 11.85M | 326.93K |
| Working Capital Changes | 22.81M | 1.32M | 18.06M | 2.36M | -20.54M | -14.49M | 992K | 3.45M |
| Change in Receivables | -8.47M | -12.58M | -5.77M | -4.5M | -19.66M | -2.99M | -6.76M | -4.44M |
| Change in Inventory | -20.85M | -6.84M | 3.64M | -4.38M | -1.73M | -1.84M | -465K | -1.13M |
| Change in Payables | 63.9M | 19.64M | 9.21M | 5.06M | -6.19M | 2.92M | 3.76M | 5.53M |
| Cash from Investing | -5.47M | -3.07M | 46.21M | 62.64M | -131.61M | -12.15M | -8.84M | -1.2M |
| Capital Expenditures | -6.22M | -3.2M | -3.79M | -4.57M | -5.53M | -2.85M | -1.19M | -1.2M |
| CapEx % of Revenue | 1% | 0.64% | 0.96% | 1.41% | 2.19% | 1.4% | 0.64% | 0.78% |
| Acquisitions | -5.02K | 0 | 0 | -4.46M | -8.58M | -9.11M | -150K | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 126K | 0 | 0 | 0 | -200K | -7.5M | 0 |
| Cash from Financing | -9.83M | 11.56M | -3.49M | -6.85M | 92.21M | 154.01M | 11.89M | -1.81K |
| Debt Issued (Net) | -26K | -20.04M | -39K | -101K | 109.94M | -7.25M | 12.18M | -1.81K |
| Equity Issued (Net) | 4.42M | 32.63M | 75K | -1.02M | -9M | 20M | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | -1.02M | -9M | 0 | 0 | 0 |
| Other Financing | -14.23M | -1.04M | -3.53M | -5.73M | -8.74M | 141.26M | -293K | 0 |
| Net Change in Cash | 49.96M | -16.1M | 16.18M | 19.48M | -101.16M | 109.18M | 3.55M | 2.41M |
| Free Cash Flow | 26.86M | -27.79M | -30.33M | -40.88M | -67.28M | -35.73M | -686K | 2.41M |
| FCF Margin % | 4.33% | -5.53% | -7.71% | -12.61% | -26.65% | -17.6% | -0.37% | 1.55% |
| FCF Growth % | - | - | 25.82% | 39.24% | -88.33% | -5108.02% | -128.46% | - |
| FCF per Share | 0.03 | -0.30 | -0.40 | -0.55 | -0.83 | -0.54 | -0.01 | 0.04 |
| FCF Conversion (FCF/Net Income) | -0.76x | 0.41x | 0.41x | 0.44x | -406.29x | 2.99x | -0.04x | -0.90x |
| Interest Paid | 2.63M | 3.91M | 0 | 4.51M | 224K | 275K | 227K | 3.38K |
| Taxes Paid | 0 | 0 | 0 | 403K | 150K | 1.73M | 207K | 61.27K |
Quick answers to the most common questions about buying STLN stock.
Starling Oncology, Inc. (STLN) generated $-24.6M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Starling Oncology, Inc. (STLN) reported negative free cash flow of $27.8M in 2025, indicating capital requirements exceeded cash from operations.
Starling Oncology, Inc. (STLN) spent $3.2M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Persistent operating losses
Metrics are mathematically derived from official filings.
Cash Conversion Diverges from Losses
In 2026Q2, TOI reported a net loss of $9.8M but generated $9.7M in operating cash flow, a swing driven by a $15.2M working capital benefit, per the latest quarterly report.
The positive operating cash flow in 2026Q2 appears to be largely a function of working capital timing rather than underlying earnings improvement, as net income remained negative. The OCF/NI ratio of -0.99 in 2026Q2 underscores the disconnect, with cash flow benefiting from collections or payables management. Investors should monitor whether this working capital tailwind reverses in subsequent quarters, as the prior two quarters showed negative operating cash flow despite similar loss levels.
FCF Turns Positive but Volatile
Free cash flow swung to $7.8M in 2026Q2 from -$3.3M in 2026Q1, yet the trailing four quarters show a cumulative FCF of -$9.9M, based on reported figures.
The positive FCF in 2026Q2 is a notable inflection, but it is inconsistent with the broader trend of negative FCF in most quarters over the past two years. The FCF margin of 4.8% in 2026Q2 is the first positive reading since 2024Q4, suggesting that revenue growth is beginning to translate into cash generation, albeit unevenly. However, the cumulative FCF remains negative, indicating that the company has not yet reached sustainable cash flow positivity.
Working Capital Swings Drive Cash Flow
Working capital changes contributed $15.2M to operating cash flow in 2026Q2, reversing a -$6.2M drag in 2025Q3, according to the cash flow statement.
The volatility in working capital changes is a dominant factor in TOI's cash flow, with swings of over $20M between quarters. This suggests that the company's cash flow is heavily influenced by the timing of receivables and payables, which may not be sustainable. The positive contribution in 2026Q2 could indicate improved collections or delayed payments, but it also raises questions about the quality of earnings, as the underlying net loss persists.
Minimal Capex Reflects Asset-Light Model
Capital expenditures averaged just 0.8% of revenue over the last four quarters, with 2026Q2 CapEx of $1.9M, per the latest financial data.
TOI's capital intensity is very low, which is consistent with a services-based healthcare model that does not require heavy investment in fixed assets. This means that the company's cash flow is less burdened by maintenance capex, allowing more of its operating cash flow to be available for other uses. However, the low capex also suggests limited investment in growth infrastructure, which may constrain future expansion if the company needs to scale its facilities.
No Capital Returns, Focus on Operations
TOI paid no dividends and made no buybacks in any of the last ten quarters, with all cash flow directed toward operations, as reported in the cash flow statements.
The absence of capital returns is typical for a company in a loss-making phase, as it conserves cash to fund operations and potential growth. The lack of acquisition activity, with only a small $126K outflow in 2025Q4, suggests that management is not pursuing aggressive M&A, which may be prudent given the cash constraints. Investors should monitor whether the company begins to return capital once it achieves sustained profitability.
Cumulative Losses Outpace Cash Burn
Over the last ten quarters, TOI's cumulative net loss of $137.6M exceeded its cumulative operating cash outflow of $48.5M, based on reported quarterly data.
The significant gap between cumulative net income and operating cash flow indicates that a large portion of the reported losses are non-cash in nature, primarily from depreciation, amortization, and stock-based compensation. This suggests that the company's cash burn is less severe than its accounting losses imply, which could provide some cushion. However, the persistent negative operating cash flow in most quarters still points to ongoing cash consumption that will require external funding if losses continue.
What Could Invalidate the Base Case
Despite the positive 2026Q2 operating cash flow, the reliance on working capital swings and persistent net losses suggest that cash generation may not be sustainable, per the cash flow data.
The cash flow statement obscures the underlying cash burn by showing a positive quarter driven by working capital timing, which may reverse. Additionally, the low capex and lack of investment could hinder growth, while the cumulative losses still exceed cash outflows, indicating that the company may need external funding. Investors should be cautious about extrapolating the 2026Q2 cash flow improvement without evidence of sustained operational profitability.